Navigation Links
DURECT Corporation Announces Third Quarter 2010 Financial Results
Date:11/3/2010

ses, with late-stage development programs including REMOXY, POSIDUR, ELADUR, and TRANSDUR-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR™, ELADUR™, and DURIN™ are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

DURECT Forward-Looking StatementThe statements in this press release regarding our projected financial results including annual cash burn, the anticipated resubmission of the REMOXY NDA, the potential acquisition of King Pharmaceuticals by Pfizer, our U.S. pivotal Phase III clinical trial (BESST) for POSIDUR including the anticipated timing of completion of the trial and patient enrollment numbers, potential milestone payments and royalties receivable from Hospira, Phase IIb trial for ELADUR including anticipated patient enrollment numbers and timing thereof, our intention to enter into collaborations with respect to TRANSDUR-Sufentanil and our ORADUR-ADHD Phase I trial, the potential benefits and uses of our drug candidates are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, delays and additional costs due to requirements imposed by regulatory agencies on our drug candidates, unexpected results and adverse events fro
'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. DURECT Corporation Invites You to Join Its Second Quarter 2010 Earnings Conference Call
2. DURECT to Present at the BMO Capital Markets Focus on Healthcare Conference
3. DURECT Corporation Secures $50 Million Committed Equity Financing Facility
4. DURECT Reports Data From European Phase IIb Hysterectomy Study of POSIDUR(TM) (SABER(TM)-Bupivacaine)
5. DURECT to Present at the Jefferies Global Life Sciences Conference
6. DURECT to Present at the Rodman & Renshaw Global Healthcare Conference
7. DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call
8. DURECT to Present at the Barclays Capital Global Healthcare Conference
9. DURECT to Present at the Cowen and Company Healthcare Conference
10. DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results
11. DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014  ResMed Inc. (NYSE: RMD ) ... fiscal year ended June 30, 2014.  Revenue for the quarter ... 30, 2013 (a 1 percent decrease on a constant currency ... percent compared to the quarter ended June 30, 2013. Diluted ... of 22 percent compared to the quarter ended June 30, ...
(Date:7/31/2014)... , July 31, 2014  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Conference, New York, NY Wednesday, August ... Baird Health Care Conference, New York, NY ... , Accessing Live Webcasts To access the live ...
(Date:7/31/2014)... Conn. , July 31, 2014  UBM Medica ... a leading online community for oncologists, presents exclusive slide ... that are essential to quality cancer care. ... journal ONCOLOGY , offers news, blogs, and podcasts ... for oncologists highlighting quality cancer care: , End-of-life ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Cepheid to Webcast Upcoming Financial Presentations 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3
(Date:8/1/2014)... New York (PRWEB) August 01, 2014 ... ) on behalf of women who allegedly experienced the ... power morcellators in gynecological surgeries, Bernstein Liebhard LLP notes ... withdraw a number of power morcellators marketed by its ... report from The New York Times, some critics of ...
(Date:8/1/2014)... Rochelle, NY, August 1, 2014Lesbian, gay, bisexual, and transgender ... the same problems as some of their heterosexual and ... they often face additional physiological and legal challenges ... recent advances in assisted reproduction options is presented in ... Future Possibilities ," published in LGBT Health ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Market ... research reports have been added to its catalogue. ... Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing ... key pharma industry drivers include, among others, increasing ... personal hygiene. In 2015, the pharma market in ...
(Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Patients with ... pulmonary disease (COPD) have a new weapon to battle ... Thursday. The agency approved a new treatment, ... the third leading killer of Americans. COPD, which is ... as chronic bronchitis and emphysema. Patients with ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 The North ... endpoint security solutions market in North America with analysis ... grow from around $3.53 billion in 2014 to $4.77 ... 2014 to 2019. , Browse through the TOC of ... an idea of the in-depth analysis provided. It also ...
Breaking Medicine News(10 mins):Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:Advances in assisted reproduction create more options and new legal issues for LGBT couples 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3Health News:FDA Approves New Treatment for People With COPD 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4
... promote cancer screening by announcing that only one in five ... to have an examination. But a new study published in ... Psychological Science, finds that this well-meaning message has the exact ... get screened. In an earlier study, Monika Sieverding ...
... HealthDay Reporter , MONDAY, July 26 (HealthDay News) ... the clot-dissolving drug tPA from 3 hours to up to ... any significant delays in treatment and appears to be a ... there was a slight increased risk of death and bleeding ...
... , MONDAY, July 26 (HealthDay News) -- Too many ... prostate-specific antigen (PSA) is normal or below normal, still ... evidence has shown that among older men with low-risk ... but another condition. For these men, watchful waiting is ...
... studies that compares two treatments for preventing strokes due carotid artery ... UT Southwestern Medical Center physician reports in an editorial in today,s ... "The most recent data on treatment options for carotid artery disease ... Dr. Ethan Halm, chief of the William T. and Gay F. ...
... Reporter , MONDAY, July 26 (HealthDay News) -- Doctors across ... open up clogged neck arteries to help prevent stroke, a ... fills up major arteries supplying blood to the brain, greatly ... the condition: an artery-scraping surgery called endarterectomy; the placement of ...
... cancer survival is associated with increased risk of long-term ... the July 26 issue of Archives of Internal ... to background in the article, childhood cancer survival rates ... roughly 70 to 80 percent currently. The authors also ...
Cached Medicine News:Health News:Few people are doing it, so why should I? Motivating men to seek cancer screening 2Health News:Longer Time Frame for Clot-Busting Drug May Help Beat Stroke 2Health News:Longer Time Frame for Clot-Busting Drug May Help Beat Stroke 3Health News:Most Men With Low-Risk Prostate Cancer Treated Aggressively, Study Shows 2Health News:Most Men With Low-Risk Prostate Cancer Treated Aggressively, Study Shows 3Health News:Surgery or stenting for carotid artery disease? Question remains 2Health News:Surgery or stenting for carotid artery disease? Question remains 3Health News:Stroke Prevention Treatment Varies Widely Across U.S. 2Health News:Stroke Prevention Treatment Varies Widely Across U.S. 3Health News:Stroke Prevention Treatment Varies Widely Across U.S. 4Health News:Childhood cancer survivors may have abnormal long-term cardiac function 2
... can be difficult for persons who have ... cord injuries and for children with poor ... other motor or coordination problems. The FoamWrap ... and coordination. Soft foam-lined material provides light ...
... a low profile contour at the palmar crease ... is an excellent choice to treat mild to ... or for wear following cast removal. The ... pile cinch fasteners provides support and compression to ...
... to treat DeQuervain's Tendonitis, strains and sprains ... advanced carpal tunnel syndrome and cumulative trauma ... Distal palmar crease contour allows for 90 ... Constructed from an open cell urethane ...
... is a solid, one-piece custom wrist orthotic designed to ... , ,Indications: , Wrist reconstruction , ... , Coles fracture - distal radius , ... , ORIF - Open reduction and internal ...
Medicine Products: